- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06424262
표준 인공와우(CI622)를 이식한 성인과 비교하여 CI622D 덱사메타손 방출 인공와우를 이식한 성인의 성능 및 청력 관련 결과 (DETECT)
새로 이식된 성인 집단에서 표준 슬림 직선 전극(CI622)과 비교하여 임피던스 감소에 있어 덱사메타손 용출 슬림 직선 전극(CI622D)의 효능을 평가하는 중추적, 전향적, 다기관, 무작위 대조, 맹검 조사 언어 이후, 양측성, 중등도 내지 심도 감각신경성 청력 손실.
This clinical study will test a newly developed cochlear implant known as CI622D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation, which is common after any surgical procedure. The goal is to learn if there are added benefits in implant performance and hearing outcomes with the dexamethasone-releasing cochlear implant (CI622D) vs. the standard cochlear implant (CI622) without dexamethasone. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve. The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing ability and their overall general health.
연구 개요
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Freiburg Im Breisgau
-
Freiburg im Breisgau, Freiburg Im Breisgau, 독일
- Universitätsklinikum Freiburg
-
-
Lower Saxony
-
Hanover, Lower Saxony, 독일
- Medizinische Hochschule Hannover
-
-
-
-
-
Manchester, 영국
- Manchester Royal Infirmary
-
-
-
-
-
Lille, 프랑스
- Centre Hospitalier Universitaire de Lille
-
Paris, 프랑스
- Hôpital Universitaire Pitié-Salpêtrière
-
Toulouse, 프랑스
- Centre Hospitalier Universitaire Toulouse
-
-
-
-
New South Wales
-
Sydney, New South Wales, 호주
- Westmead Private Hospital
-
Sydney, New South Wales, 호주
- Royal Prince Alfred Hospital
-
Sydney, New South Wales, 호주
- Macquarie University
-
-
Victoria
-
Melbourne, Victoria, 호주
- St Vincent Private Hospital
-
Melbourne E., Victoria, 호주
- Royal Victorian Eye and Ear Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Aged 18 years or older (at time of consent)
- Clinically established post-linguistic bilateral moderately severe to profound sensorineural hearing loss
- Meets local candidacy criteria for cochlear implantation
- Compromised functional hearing with a hearing aid in the ear to be implanted
- Willing to participate in and comply with all requirements of the protocol, including willingness to be randomised to either arm
- Evidence of pneumococcal vaccination (e.g., Pneumovax) according to local guidelines prior to randomisation
- Candidate is proficient in the language used to assess speech perception performance
- Willing and able to provide written informed consent.
Exclusion Criteria:
- Planned for a partial insertion of the electrode array
- Intra-axial (within the brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted
- Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment
- Active autoimmune disease or active immunosuppressive therapy
- Any of the following in the ear to be implanted within 3 months prior to enrolment: history of prior otologic surgery including grommets, or tympanic membrane perforation
- Previously reported diagnosis of auditory neuropathy, in the ear to be implanted
- Previously reported diagnosis, in the ear to be implanted, of Large Vestibular Aqueduct Syndrome (LVAS), Meniere's disease, or cochlear hydrops
- Ossification, otosclerosis, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by imaging, in the ear to be implanted
- Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, temporo- parietal skull fracture or CSF leaks
- History of bacterial meningitis
- Known allergic reaction or contraindication to dexamethasone or corticosteroids
- Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the subject
- Severe, or poorer, sensorineural hearing loss of more than 20 years, as reported by the subject, in the ear to be implanted
- Prior cochlear implantation, in either ear
- Medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted
- Medical or psychological conditions that contraindicate general anaesthesia, surgery or participation in the clinical investigation, as determined by the investigator
- Women who are pregnant
- Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator
- Additional disabilities that may affect the subject's participation or safety during the clinical investigation, as determined by the Investigator
- Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator
- Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as spouse, parent, child, or sibling to the study candidate
- Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation
- Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by investigator or Sponsor to not impact this investigation)
- Subjects recruited at a French site who are not affiliated with social security
- Subjects recruited at a French site who are under legal protection.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: CI622D
Investigational Medical Device (IMD) |
A dexamethasone-eluting Slim Straight electrode |
|
활성 비교기: CI622
An approved medical device |
A standard Slim Straight electrode |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Difference in the mean impedance between CI622D and CI622
기간: 6 months post-activation
|
Mean monopolar impedance measured across the active electrodes of the implant for each participant. |
6 months post-activation
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events of the CI622D and CI622
기간: Throughout study (12 months)
|
Percentage of the number of participants who experience an adverse event for the CI622D group and the CI622 group |
Throughout study (12 months)
|
|
Difference in the proportion of participants with preservation of low frequency residual hearing with CI622D compared with CI622
기간: Pre-implantation to 6 months post activation
|
The proportion of participants achieving ≤ 30 dB change in the low frequency pure tone average (LFPTA) (250 Hz and 500 Hz). This measure will be applied to the subgroup of participants who have a LFPTA < 80 dB HL at the pre-operative baseline. |
Pre-implantation to 6 months post activation
|
|
Mean change (within-subject) in word recognition score in the preferred unilateral listening mode in quiet with the CI622D
기간: Pre-implantation to 6 months post-activation
|
Change in percent correct word recognition score |
Pre-implantation to 6 months post-activation
|
|
Mean change (within-subject) in word recognition score in the preferred bilateral listening mode in quiet with the CI622D
기간: Pre-implantation to 6 months post-activation
|
Change in percent correct word recognition score |
Pre-implantation to 6 months post-activation
|
|
Difference in mean (within-subject) change in word recognition score in the preferred unilateral listening mode in quiet with the CI622D compared with CI622
기간: Pre-implantation to 12 months post-activation
|
Change in percent correct word recognition score |
Pre-implantation to 12 months post-activation
|
|
Difference in mean (within-subject) change in word recognition score in the preferred bilateral listening mode in quiet from pre-implantation to post-activation with CI622D compared with CI622
기간: Pre-implantation to 12 months post-activation
|
Change in percent correct word recognition score |
Pre-implantation to 12 months post-activation
|
|
Difference in mean (within-subject) change in sentence recognition score in noise in the preferred unilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622
기간: Pre-implantation to 12 months post-activation
|
Change in percent correct sentence recognition score (Matrix test + 10 SNR) |
Pre-implantation to 12 months post-activation
|
|
Difference in mean (within-subject) change in sentence recognition score in noise in the preferred bilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622
기간: Pre-implantation to 12 months post-activation
|
Change in percent correct sentence recognition score (Matrix test + 10 SNR) |
Pre-implantation to 12 months post-activation
|
|
Characterization of four-point nested impedances and monopolar impedance of the CI622D and CI622
기간: Activation, 12 months post-activation
|
Group mean impedance measured across the active electrodes for four-point nested impedance and MP1+2 impedance for the CI622D and CI622 |
Activation, 12 months post-activation
|
|
Characterization of mean estimated sound processor battery life for CI622D and CI622
기간: 12 months post-activation
|
The estimated sound processor battery life (hours per day) as calculated by the programming software |
12 months post-activation
|
|
Difference in mean within-subject changes in global score on the Speech, Spatial, and Qualities of Hearing Scale (SSQ12) between CI622D and CI622
기간: Pre-implantation to 12 months post-activation
|
Speech, Spatial, and Qualities of Hearing Scale global score (SSQ-12). Scores range from 0 to 10, where higher scores indicate greater ability (less hearing disability). |
Pre-implantation to 12 months post-activation
|
|
Difference in mean within-subject changes in global Health Utilities Index III (HUI3) between CI622D and CI622
기간: Pre-implantation to 12 months post-activation
|
Health Utilities Index (HUI 2/3) global score. Scores range from -0.36 to 1.00, where a negative score represents a state "worse than dead" and a top score of 1.00 is "perfect health". |
Pre-implantation to 12 months post-activation
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .